NASDAQ : MLYS
Mineralys Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 18.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.61B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 69.20M | 38.59M | 23.82M | 14.30M | 5.23M | 2.42M |
| Research & Development | 301.59M | 132.01M | 168.58M | 70.36M | 26.25M | 16.31M |
| Operating Expenses | 370.79M | 170.60M | 192.40M | 84.66M | 31.48M | 18.73M |
| Operating Income | -370.79M | -170.60M | -192.40M | -84.66M | -31.48M | -18.73M |
| Interest Expense | -27.00K | |||||
| Interest & Investment Income | 21.19M | 15.95M | 14.59M | 12.76M | 1.68M | |
| Other Non Operating Income (Expenses) | 23.00K | 5.00K | 3.00K | 4.00K | 1.00K | |
| EBT Excluding Unusual Items | -349.58M | -154.65M | -177.81M | -71.90M | -29.80M | -18.75M |
| Other Unusual Items | -657.00K | |||||
| Pretax Income | -349.58M | -154.65M | -177.81M | -71.90M | -29.80M | -19.41M |
| Net Income | -349.58M | -154.65M | -177.81M | -71.90M | -29.80M | -19.41M |
| Net Income to Common | -349.58M | -154.65M | -177.81M | -71.90M | -29.80M | -19.41M |
| Shares Outstanding (Basic) | 79.88M | 67.66M | 48.54M | 36.19M | 5.17M | 4.98M |
| Shares Outstanding (Diluted) | 79.88M | 67.66M | 48.54M | 36.19M | 5.17M | 4.98M |
| EPS (Basic) | -4.38 | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 |
| EPS (Diluted) | -4.38 | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 |
| Free Cash Flow | -138.80M | -142.43M | -166.41M | -81.17M | -29.22M | -14.56M |
| Free Cash Flow Per Share | -1.74 | -2.10 | -3.43 | -2.24 | -5.66 | -2.92 |
| EBITDA | -370.75M | -170.54M | -192.36M | |||
| D&A For EBITDA | 39.00K | 59.00K | 43.00K | |||
| EBIT | -370.79M | -170.60M | -192.40M | -84.66M | -31.48M | -18.73M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 138.27M | 172.92M | 114.09M | 49.30M | 87.70M | 10.61M |
| Short-Term Investments | 523.14M | 483.71M | 84.10M | 187.26M | 22.41M | |
| Cash & Short-Term Investments | 661.41M | 656.63M | 198.19M | 236.57M | 110.11M | 10.61M |
| Prepaid Expenses | 4.39M | 4.75M | 7.16M | 12.54M | 2.70M | 460.00K |
| Restricted Cash | 50.00K | |||||
| Total Current Assets | 665.80M | 661.39M | 205.35M | 249.10M | 112.81M | 11.12M |
| Property, Plant & Equipment | 27.00K | 38.00K | 53.00K | |||
| Long-Term Investments | 2.48M | |||||
| Long-Term Deferred Charges | 200.00K | 200.00K | 400.00K | 1.60M | 3.00K | |
| Other Long-Term Assets | 1.82M | 182.00K | 99.00K | 51.00K | 31.00K | |
| Total Assets | 667.85M | 661.81M | 205.90M | 251.64M | 114.44M | 11.12M |
| Accounts Payable | 1.07M | 2.02M | 479.00K | 601.00K | 1.91M | 763.00K |
| Accrued Expenses | 18.25M | 13.10M | 14.17M | 9.88M | 6.16M | 4.29M |
| Total Current Liabilities | 19.32M | 15.11M | 14.65M | 10.48M | 8.07M | 5.05M |
| Total Liabilities | 116.94M | 15.11M | 14.65M | 10.48M | 8.07M | 5.05M |
| Common Stock | 9.00K | 8.00K | 5.00K | 4.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 1.29B | 1.10B | 493.77M | 365.86M | 540.00K | 85.00K |
| Retained Earnings | -737.58M | -457.17M | -302.52M | -124.71M | -52.81M | -23.01M |
| Total Common Equity | 550.92M | 646.69M | 191.26M | 241.15M | -52.27M | -22.93M |
| Shareholders' Equity | 550.92M | 646.69M | 191.26M | 241.15M | 106.38M | 6.07M |
| Total Liabilities & Equity | 667.85M | 661.81M | 205.90M | 251.64M | 114.44M | 11.12M |
| Total Debt | 97.62M | |||||
| Net Cash (Debt) | 563.79M | 656.63M | 198.19M | 236.57M | 110.11M | 10.61M |
| Net Cash Per Share | 7.06 | 9.71 | 4.08 | 6.54 | 21.31 | 2.13 |
| Filing Date Shares Outstanding | 88.41M | 82.40M | 49.84M | 49.63M | 40.86M | 5.44M |
| Total Common Shares Outstanding | 88.35M | 81.54M | 49.82M | 41.13M | 6.42M | 5.44M |
| Working Capital | 646.48M | 646.27M | 190.71M | 238.62M | 104.74M | 6.07M |
| Book Value Per Share | 6.24 | 7.93 | 3.84 | 5.86 | -8.14 | -4.21 |
| Tangible Book Value | 550.92M | 646.69M | 191.26M | 241.15M | -52.27M | -22.93M |
| Tangible Book Value Per Share | 6.24 | 7.93 | 3.84 | 5.86 | -8.14 | -4.21 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -349.58M | -154.65M | -177.81M | -71.90M | -29.80M | -19.41M |
| Depreciation & Amortization | 39.00K | 59.00K | 43.00K | |||
| Loss (Gain) From Sale of Investments | -15.87M | -9.88M | -9.40M | -6.87M | -649.00K | |
| Stock-Based Compensation | 25.03M | 19.32M | 11.34M | 5.06M | 455.00K | 80.00K |
| Other Operating Activities | 200.00M | 684.00K | ||||
| Change in Accounts Payable | -3.84M | 427.00K | 4.16M | 2.42M | 3.01M | 4.47M |
| Change in Other Net Operating Assets | 5.30M | 2.30M | 5.36M | -9.88M | -2.24M | -386.00K |
| Operating Cash Flow | -138.79M | -142.42M | -166.31M | -81.17M | -29.22M | -14.56M |
| Capital Expenditures | -15.00K | -15.00K | -96.00K | |||
| Investment in Securities | -284.14M | -389.74M | 115.06M | -160.47M | -21.76M | |
| Investing Cash Flow | -484.16M | -389.75M | 114.96M | -160.47M | -21.76M | |
| Total Debt Issued | 97.50M | |||||
| Net Debt Issued (Repaid) | 97.50M | |||||
| Issuance of Common Stock | 563.29M | 591.39M | 116.58M | 203.25M | ||
| Other Financing Activities | -1.36M | -391.00K | -435.00K | -1.63M | ||
| Financing Cash Flow | 659.42M | 591.00M | 116.14M | 203.25M | 128.02M | 23.81M |
| Net Cash Flow | 36.48M | 58.83M | 64.79M | -38.40M | 77.04M | 9.25M |
| Free Cash Flow | -138.80M | -142.43M | -166.41M | -81.17M | -29.22M | -14.56M |
| Free Cash Flow Per Share | -1.74 | -2.10 | -3.43 | -2.24 | -5.66 | -2.92 |
| Levered Free Cash Flow | -203.46M | -84.38M | -99.43M | -55.27M | -18.40M | -7.62M |
| Unlevered Free Cash Flow | -203.58M | -84.38M | -99.43M | -55.27M | -18.40M | -7.61M |
| Change in Working Capital | 1.47M | 2.73M | 9.52M | -7.47M | 772.00K | 4.08M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.49B | 2.87B | 612.65M | 353.50M | ||
| Enterprise Value | 924.09M | 2.28B | 349.05M | 99.74M | ||
| Last Close Price | 18.18 | 36.29 | 12.31 | 8.60 | ||
| PB Ratio | 2.92 | 4.44 | 3.20 | 1.47 | ||
| P/TBV Ratio | 2.92 | 4.44 | 3.20 | 1.47 | ||
| Debt / Equity Ratio | 0.18 | |||||
| Net Debt / Equity Ratio | -1.02 | -1.01 | -1.04 | -0.98 | -1.03 | -1.75 |
| Net Debt / EBITDA Ratio | 1.52 | 3.85 | 1.03 | |||
| Net Debt / FCF Ratio | 4.06 | 4.61 | 1.19 | 2.91 | 3.77 | 0.73 |
| Quick Ratio | 34.24 | 43.45 | 13.53 | 22.57 | 13.65 | 2.10 |
| Current Ratio | 34.46 | 43.76 | 14.02 | 23.77 | 13.98 | 2.20 |
| Return on Equity (ROE) | -80.88% | -36.91% | -82.24% | -41.38% | -53.00% | -1,568.96% |
| Return on Assets (ROA) | -46.18% | -24.58% | -52.56% | -28.91% | -31.34% | -185.60% |
| Return on Capital Employed (ROCE) | -57.20% | -26.40% | -100.60% | -35.10% | -29.60% | -308.40% |
| Earnings Yield | -26.00% | -5.38% | -29.02% | -20.34% | ||
| FCF Yield | -8.64% | -4.96% | -27.16% | -22.96% | ||
| Buyback Yield / Dilution | -46.24% | -39.38% | -34.13% | -600.33% | -3.67% | -7.64% |